title: FDA approves saxagliptin for type 2 diabetes.
authors.forename: Kate
authors.initials: K
authors.lastname: Traynor
mesh_terms: D000218:Adamantane / Q000031:analogs & derivatives* / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D004151:Dipeptides / Q000627:therapeutic use*; D054873:Dipeptidyl-Peptidase IV Inhibitors / Q000627:therapeutic use; D017277:Drug Approval; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D004151:Dipeptides; D054873:Dipeptidyl-Peptidase IV Inhibitors; D007004:Hypoglycemic Agents; C502994:saxagliptin; D000218:Adamantane